These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 30276763)
1. Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer. Jauch SF; Riethdorf S; Sprick MR; Schütz F; Schönfisch B; Brucker SY; Deutsch TM; Nees J; Saini M; Becker LM; Burwinkel B; Sinn P; Marmé F; Pantel K; Jäger D; Sohn C; Trumpp A; Wallwiener M; Schneeweiss A Breast Cancer Res Treat; 2019 Jan; 173(1):155-165. PubMed ID: 30276763 [TBL] [Abstract][Full Text] [Related]
2. Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients. Wallwiener M; Riethdorf S; Hartkopf AD; Modugno C; Nees J; Madhavan D; Sprick MR; Schott S; Domschke C; Baccelli I; Schönfisch B; Burwinkel B; Marmé F; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A BMC Cancer; 2014 Jul; 14():512. PubMed ID: 25015676 [TBL] [Abstract][Full Text] [Related]
3. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204 [TBL] [Abstract][Full Text] [Related]
4. Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer. Deutsch TM; Riethdorf S; Nees J; Hartkopf AD; Schönfisch B; Domschke C; Sprick MR; Schütz F; Brucker SY; Stefanovic S; Sohn C; Pantel K; Trumpp A; Schneeweiss A; Wallwiener M Breast Cancer Res Treat; 2016 Nov; 160(2):277-290. PubMed ID: 27696083 [TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845 [TBL] [Abstract][Full Text] [Related]
6. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer. Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903 [TBL] [Abstract][Full Text] [Related]
7. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327 [TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer. Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129 [TBL] [Abstract][Full Text] [Related]
9. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830 [TBL] [Abstract][Full Text] [Related]
10. Detection of circulating tumor cells in breast cancer patients: prognostic predictive role. Turker I; Uyeturk U; Sonmez OU; Oksuzoglu B; Helvaci K; Arslan UY; Budakoglu B; Alkis N; Aksoy S; Zengin N Asian Pac J Cancer Prev; 2013; 14(3):1601-7. PubMed ID: 23679243 [TBL] [Abstract][Full Text] [Related]
11. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110 [TBL] [Abstract][Full Text] [Related]
12. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653 [TBL] [Abstract][Full Text] [Related]
13. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222 [TBL] [Abstract][Full Text] [Related]
14. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial. Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W; BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743 [TBL] [Abstract][Full Text] [Related]
15. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. Wang C; Mu Z; Chervoneva I; Austin L; Ye Z; Rossi G; Palazzo JP; Sun C; Abu-Khalaf M; Myers RE; Zhu Z; Ba Y; Li B; Hou L; Cristofanilli M; Yang H Breast Cancer Res Treat; 2017 Jan; 161(1):83-94. PubMed ID: 27771841 [TBL] [Abstract][Full Text] [Related]
16. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. Peeters DJ; van Dam PJ; Van den Eynden GG; Rutten A; Wuyts H; Pouillon L; Peeters M; Pauwels P; Van Laere SJ; van Dam PA; Vermeulen PB; Dirix LY Br J Cancer; 2014 Jan; 110(2):375-83. PubMed ID: 24366294 [TBL] [Abstract][Full Text] [Related]
17. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor. Beije N; Onstenk W; Kraan J; Sieuwerts AM; Hamberg P; Dirix LY; Brouwer A; de Jongh FE; Jager A; Seynaeve CM; Van NM; Foekens JA; Martens JW; Sleijfer S Neoplasia; 2016 Nov; 18(11):647-653. PubMed ID: 27764697 [TBL] [Abstract][Full Text] [Related]
18. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer. Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482 [TBL] [Abstract][Full Text] [Related]
19. Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer. Jacot W; Mazel M; Mollevi C; Pouderoux S; D'Hondt V; Cayrefourcq L; Bourgier C; Boissiere-Michot F; Berrabah F; Lopez-Crapez E; Bidard FC; Viala M; Maudelonde T; Guiu S; Alix-Panabières C Clin Chem; 2020 Aug; 66(8):1093-1101. PubMed ID: 32712650 [TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Cristofanilli M; Broglio KR; Guarneri V; Jackson S; Fritsche HA; Islam R; Dawood S; Reuben JM; Kau SW; Lara JM; Krishnamurthy S; Ueno NT; Hortobagyi GN; Valero V Clin Breast Cancer; 2007 Feb; 7(6):471-9. PubMed ID: 17386124 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]